1.Research progress of traditional Chinese medicine regulating PI3K/Akt signaling pathway to promote chronic wound healing
Zhenhui ZHU ; Zhi LI ; Yu LENG ; Tao CAI ; Xuefa SHEN ; Xianxue XIANG ; Yongxin HUANG
China Pharmacy 2025;36(8):1019-1024
The pathogenesis of chronic wound healing is complex. It is often difficult to heal due to a long course of disease, difficulty in treatment, and it seriously affects the quality of life in patients. The active ingredients, couplet medicinals, and compound formulas of traditional Chinese medicine (TCM) possess unique advantages in the treatment of chronic wound healing. The phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) signaling pathway is extremely critical in the treatment of chronic wound healing by regulating a series of biological processes, including cell apoptosis, angiogenesis, and inflammatory responses. This article reviews the relevant research on the regulation of the PI3K/Akt signaling pathway by TCM to promote chronic wound healing. It has been found that the active ingredients of TCM (such as geniposide, astragaloside, and ginsenosides, etc.), and compound formulas (such as Chonghe ointment, Huanglian ointment, Shirun shaoshang ointment, etc.) mainly reduce inflammatory responses, promote angiogenesis, regulate cell autophagy, and accelerate wound healing by activating the PI3K/Akt signaling pathway; at the same time, there are also a few couplet medicinals( such as Huangqi-Honghua) and compound formulas (such as Xiangpi Shengji ointment) that exert anti-inflammatory effects by inhibiting this signaling pathway, to promote wound healing.
2.Morphological classification of postero-superior protuberance of calcaneus and its relationship with Haglund deformity.
Lei ZHANG ; Man ZHANG ; Lu JIANG ; Lei HUANG ; Yu WU ; Rao LENG ; Houyin SHI ; Guoyou WANG
Chinese Journal of Reparative and Reconstructive Surgery 2025;39(5):592-597
OBJECTIVE:
To explore the morphological characteristics of the postero-superior protuberance of the calcaneus and to explore its relationship with Haglund malformation.
METHODS:
Ankle lateral X-ray films of 391 hospitalized patients between May 2021 and June 2024 were retrospectively collected. The morphological parameters of the postero-superior protuberance of the calcaneus were measured, including the length of the base, the height of the base, and the tip angle of the postero-superior protuberance of the calcaneus, and the morphological types were classified according to the above parameters, including the peak type, the hill type, and the flat type. The related parameters of Haglund malformation were measured, including Fowler-Philipp angle (FPA), calcaneal pitch angle (CPA), parallel pitch line (PPL), Chauveaux-Liet angle (CLA), and X/Y ratio (total calcaneal length/length of greater tuberosity of calcaneus). The differences of the morphological parameters of the postero-superior protuberance of the calcaneus and the related indicators of Haglund deformity among the three types and between the males and the females were compared and analyzed, and the differences of the positive numbers of the related indicators of Haglund deformity among the three types were compared.
RESULTS:
According to the morphological parameters of the postero-superior protuberance of the calcaneus, there were 64 cases of peak type, 245 cases of hill type, and 82 cases of flat type. There was no significant difference in the length of the base of the postero-superior protuberance of the calcaneus, CPA, CLA, and X/Y ratio among the three types ( P>0.05). Among the three types, the peak type had the largest FPA and the flat type had the smallest ( P<0.05); the peak type had the smallest tip angle of the postero-superior protuberance of the calcaneus and the flat type had the largest ( P<0.05); the positive rate of PPL in the hill type was significantly higher than that in the peak type and flat type ( P<0.05); the height of the base of the postero-superior protuberance of the calcaneus in the flat type was the smallest ( P<0.05). FPA, CPA, CLA, PPL, and X/Y ratio were positive in 2, 42, 172, 142, and 77 patients, respectively. There was no significant difference in the number of positive Haglund deformity indicators among the three types ( P>0.05). There was no significant difference between male and female patients in the tip angle of the postero-superior protuberance of the calcaneus, FPA, the positive rate of PPL, and X/Y ratio ( P>0.05). The length and the height of the base of the postero-superior protuberance of the calcaneus, CPA, and CLA in male patients were significantly higher than those in female patients ( P<0.05).
CONCLUSION
The postero-superior protuberance of the calcaneus can be divided into three types: the peak type, the hill type, and the flat type. The peak type is more likely to suffer from Haglund deformity, and the males are more likely to suffer from Haglund deformity than the females.
Humans
;
Calcaneus/anatomy & histology*
;
Male
;
Female
;
Retrospective Studies
;
Adult
;
Middle Aged
;
Adolescent
;
Young Adult
;
Radiography
;
Child
;
Aged
3.The endovascular treatment strategies of cerebrovascular injuries in traumatic brain injury.
Shuo LENG ; Wentao LI ; Yu CAI ; Yi ZHANG
Chinese Journal of Traumatology 2025;28(2):81-90
Vasculature injury occurs rarely in traumatic brain injury but increases lifetime risk of ischemic or hemorrhage stroke. The diverse and nonspecific clinical manifestations make the diagnosis and treatment of these injuries highly challenging. With advancements in device design, endovascular treatments have become widely adopted, playing an increasingly vital role in the management of vascular diseases. The purpose of this review is to introduce and summarize endovascular treatments of traumatic cerebrovascular injury and other related pathological states after traumatic brain injury. Given the innovations of neuroendovascular devices and improvements in the techniques over the past decade, this review will outline several recent advancements in endovascular treatment strategies for cerebrovascular pathologies. Popularizing more treatment options to clinicians will benefit in dealing with a variety of clinical scenarios and reduce the overall morbidity of traumatic cerebrovascular injury.
Humans
;
Endovascular Procedures/methods*
;
Brain Injuries, Traumatic/complications*
;
Cerebrovascular Trauma/therapy*
4.Key Information Textual Research and Quality Marker Prediction Analysis of the Ancient Classic Formula Huangqin Decoc-tion
Jiahao WANG ; Limei GU ; Hao XUE ; Yu LI ; Yu CHEN ; Ziyan LENG ; Renshou CHEN
Journal of Nanjing University of Traditional Chinese Medicine 2024;40(11):1263-1274
Huangqin Decoction is a classic formula published in the Catalogue of Ancient Classical Famous Prescriptions(the Sec-ond Batch).This paper systematically collates,researches and analyzes the ancient and modern clinical literature that records Huan-gqin Decoction,sorts out key issues such as the prescription origin,composition,medicine origin,processing method,usage and dos-age,efficacy and indications of Huangqin Decoction,and performs predictive analysis on its quality markers(Q-Marker)to provide lit-erature and theoretical support for the clinical application and preparation development of Huangqin Decoction from the entire process of textual research-preparation development-quality evaluation.After analysis and research,it is found that Huangqin Decoction is de-rived from Zhang Zhongjing's Treatise on Cold Damage.It consists of Scutellaria baicalensis,Radix Paeoniae Alba,and Glycyrrhiza,with Jujube serving as the guiding herb.The medicine origin follows the 2020 edition of the Chinese Pharmacopoeia.Scutellaria ba-icalensis and Radix Paeoniae Alba are taken in the raw form;Glycyrrhiza is lightly fried and Jujubes with sliced pieces.The doasge of medicine is 11.19 of Scutellaria baicalensis,7.46 g of Radix Paeoniae Alba and Glycyrrhiza,and jujubes are added or subtracted ac-cording to the situation.The method of preparation and administration is that all herbs are added with 2 000 mL of water,decocting to 600 mL.The decoction can be consumed warm 3 times a day at any suitable time.The formula was commonly used in ancient times for dysentery,but now it is also used for other digestive system diseases such as ulcerative colitis and chronic colitis,which are mainly characterized by diarrhea.The suggested Q-markers for Huangqin Decoction are baicalin,baicalein,wogonin,paeoniflorin,glycyrrhi-zin and glycyrrhizic acid.
5.Tooth Design of Ophthalmic Microsurgical Forceps Based on Minimum Slip Force
Tianfeng LENG ; Yu ZHENG ; Shaofeng HAN ; Chenhan GUANG ; Yang YANG
Chinese Journal of Medical Instrumentation 2024;48(6):678-682
This study proposed the use of the minimum slip force as an indicator to measure the clamping ability of microsurgical forceps.By analyzing the minimum slip forces of four typical tooth types of microsurgical forceps,the clamping capacity of each type was evaluated.Among the existing tooth forms,the staggered tooth type exhibited a relatively large minimum slip force.Consequently,a new tooth-shaped structure for microsurgical forceps-the hemispherical convex structure was proposed.Simulation and experimental studies demonstrated that this new dental structure could achieve stable and reliable clamping.
6.Molecular Mechanism of Action of Astragaloside Ⅳ in Modulating Pyroptosis to Attenuate Intestinal Ischemia-reperfusion Injury Based on Experimental Validation
Liya CHANG ; Yufang LENG ; Zicen ZHAO ; Yu WANG ; Yang XING ; Dongbin LI
Chinese Journal of Experimental Traditional Medical Formulae 2024;30(19):116-123
ObjectiveTo investigate the mechanism of astragaloside-Ⅳ (AS-Ⅳ) in regulating pyroptosis to alleviate intestinal ischemia-reperfusion injury (IRI) by combining network pharmacology and in vivo experiments. MethodFirstly, the corresponding target genes of AS-Ⅳ were obtained from TraditionalChineseMedicineSystemsPharmacology(TCMSP) database and Swiss Target Prediction database, and the target genes related to intestinal IRI and Pyroptosis were obtained from GeneCards database, and the common target genes of the three were obtained by drawing Venn diagrams through unspiralized website. Protein-protein interaction (PPI) network was constructed by STRING database and Cytoscape software to screen common target genes and imported into Cytoscape software to obtain core target genes. Microbiotics platform was used for gene ontology(GO) and Kyoto encyclopedia of genes and genomes(KEGG) enrichment analysis and prediction of the mechanism of action of AS-Ⅳ in regulating Pyroptosis to alleviate intestinal IRI. Then C57/BL6J mice were randomly divided into 5 groups normal group, model group(IR), drug administration group (IR+AS-Ⅳ), nucleotide-binding oligomerization structural domain-like receptor protein 3 (NLRP3) agonist NSS group (IR+AS-Ⅳ+NSS), and NLRP3 inhibitor MCC950 group (IR+AS-Ⅳ+MCC950) by using a randomized numerical table method. The intestinal IRI model was established by clamping the superior mesenteric artery for 45 min and resuming perfusion for 2 h in the model group, the drug administration group, the NLRP3 agonist NSS group, and the NLRP3 inhibitor MCC950 group, and the normal group was only separated from the vessels without clamping. The administration group, the NLRP3 agonist NSS group, and the NLRP3 inhibitor MCC950 group were gavaged with astragaloside dissolved in 0.1% dimethylsulfoxide (50 mg·kg-1) for 3 consecutive days before modeling, with the last gavage 2 h before modeling, and the remaining two groups were gavaged with equal amounts of saline. The NLRP3 agonist NSS group was injected intraperitoneally with 4 mg·kg-1 of NSS 1 h before modeling, and the NLRP3 inhibitor MCC950 group was injected intraperitoneally with 10 mg·kg-1 of MCC950 1 h before modeling.The mice were put to death by reperfusion for 2 h, and intestinal tissues were obtained. The levels of IL-18 and IL-1β were detected by enzyme linked immunosorbent assay(ELISA), and the protein expression of thioredoxin-binding protein (TXNIP), NLRP3, Caspase-1 and pyrocatechin D (GSDMD) were detected by Western blot, and the pathological changes of intestinal tissues were evaluated by Chiu's score. ResultNetwork pharmacological analysis showed that there were 1599 targets of intestinal IRI, 199 targets of AS-Ⅳ action, 197 targets of pyroptosis, and 20 targets common to all three. There were 10 core targets, including NLRP3, TXNIP, silencing information regulator 1 (SIRT1), high mobility group protein 1 (HMGB1), interleukin-18 (IL-18), GSDMD, and metallo matrix protease-9 (MMP-9),et al. The results of in vivo experiments showed that compared with the normal group, Chiu's score was elevated in the model group, the levels of IL-18,IL-1β inflammatory factors in mouse intestinal tissues were elevated (P<0.05), and the protein expression levels of TXNIP, NLRP3, Caspase-1, and GSDMD were elevated (P<0.05). Compared with the model group,Chiu's score was decreased in the administered group and NLRP3 inhibitor MCC950 group,the level of IL-18,IL-1β inflammatory factors in the intestinal tissue of mice was decreased(P<0.05), and the level of TXNIP,NLRP3,Caspase-1,GSDMD protein expression was decreased(P<0.05). Compared with the administered group, Chiu's score was elevated in the NLRP3 agonist NSS group, the levels of IL-18, IL-1β inflammatory factors in mouse intestinal tissues were elevated (P<0.05), and the protein expression levels of NLRP3, Caspase-1, and GSDMD were elevated (P<0.05). Compared with the NLRP3 inhibitor MCC950 group, the NLRP3 agonist NSS group had elevated Chiu's scores, elevated levels of IL-18,IL-1β inflammatory factors in mouse intestinal tissues (P<0.05), and elevated levels of TXNIP,NLRP3, Caspase-1, and GSDMD protein expression (P<0.05). ConclusionNetwork pharmacological predictions were consistent with the results of in vivo experiments, and astragaloside attenuated intestinal ischemia-reperfusion injury by inhibiting cellular pyroptosis through the TXNIP-NLRP3 signaling pathway.
7.Expedited program and utilization for anticancer drug approval in China and the United States
Qi ZHU ; Huiyao HUANG ; Anqi YU ; Xinyu MENG ; Ye LENG ; Hong FANG ; Ziwei LI ; Yu TANG ; Ji LI ; Ning LI
Chinese Journal of Oncology 2024;46(9):904-910
Objective:To systematically summarize and comparatively analyze the development, establishment and usage of oncology drugs speedy review approaches in China and in the United States between 2012 and 2021.Methods:Based on National Medical Products Administration (NMPA) and Food and Drug Administration (FDA) websites, the development and current status of the speedy review approaches were consulted and summarized. Approved oncology drugs in China and in the United States (87 in China, 118 in the United States) over the past decade were analyzed using chi-square test for group comparison.Results:Five speedy approaches have been established in China and in the United States, three of which are the same, priority review, conditional approval or accelerated approval and breakthrough therapy. The rest two are special review and approval, special examination and approval in China, and fast track and real-time oncology review in the United States. Compared to the United States, speedy review approaches in China set up late (1992 vs. 2005). The overall utilization rates of the oncology drugs speedy review approaches were similar between the China and United States (90.8% vs. 92.4%, P=0.800) in the previous 10 years, and priority review have highest utilization rates in both China and the United States without significant group difference (77.0% vs. 82.2%, P=0.381); relatively low utilization rates of conditional approval (31.0% vs. 44.9%, P=0.041) and breakthrough therapy (2.3% vs. 50.0%, P<0.001) were seen in China. 52.9% of new drugs applied for special examination and approval in China and 40.7% of new drugs applied for fast track in the United States. Overall, the priority review both in China and the United States are stable, with a similar average annual utilization rate (84.8% vs. 83.7%); accelerated approval and breakthrough therapies in the United States fluctuate wildly, but the situation is tending towards stability in the last 3 years. Conclusions:Both China and the United States have established a relatively complete accelerated review system, with an overall utilization rate over 90%; China's accelerated review started late, although the overall utilization rate is close to that of the United States. The utilization rates of conditional approval and breakthrough therapy are still relatively low. Flexible usage of speedy review approaches, gaining regulatory recognition to use alternative endpoints, achieving real-time review and guidance are keys to accelerate new drug development in China.
8.Non-coding RNAs as therapeutic targets in cancer and its clinical application
Leng XUEJIAO ; Zhang MENGYUAN ; Xu YUJING ; Wang JINGJING ; Ding NING ; Yu YANCHENG ; Sun SHANLIANG ; Dai WEICHEN ; Xue XIN ; Li NIANGUANG ; Yang YE ; Shi ZHIHAO
Journal of Pharmaceutical Analysis 2024;14(7):983-1010
Cancer genomics has led to the discovery of numerous oncogenes and tumor suppressor genes that play critical roles in cancer development and progression.Oncogenes promote cell growth and proliferation,whereas tumor suppressor genes inhibit cell growth and division.The dysregulation of these genes can lead to the development of cancer.Recent studies have focused on non-coding RNAs(ncRNAs),including circular RNA(circRNA),long non-coding RNA(lncRNA),and microRNA(miRNA),as therapeutic targets for cancer.In this article,we discuss the oncogenes and tumor suppressor genes of ncRNAs associated with different types of cancer and their potential as therapeutic targets.Here,we highlight the mechanisms of action of these genes and their clinical applications in cancer treatment.Understanding the molecular mechanisms underlying cancer development and identifying specific therapeutic targets are essential steps towards the development of effective cancer treatments.
9.FOLFOX-HAIC combined with lenvatinib and immune checkpoint inhibitors for hepatocellular carcinoma after the occurrence of TACE refractoriness:analysis of efficacy and safety
Lingfeng DIAO ; Chendong WANG ; Bin LENG ; Ran YOU ; Zeyu YU ; Qingyu XU ; Guowen YIN
Journal of Interventional Radiology 2024;33(6):610-615
Objective To evaluate the efficacy and safety of fluorouracil and leucovorin and oxaliplatin(FOLFOX)regimen hepatic artery infusion chemotherapy(HAIC)combined with lenvatinib(LEN)and immune checkpoint inhibitors(ICIs)in treating patients with hepatocellular carcinoma(HCC)after the occurrence of transcatheter arterial chemoembolization(TACE)refractoriness.Methods The clinical data of 54 HCC patients who developed TACE refractoriness,were admitted to the Jiangsu Provincial Cancer Hospital of China to receive FOLFOX-HAIC combined with LEN and ICIs therapy between January 2019 and December 2022,were retrospectively analyzed.The modified Response Evaluation Criteria in Solid Tumors(mRECIST)was used to statistically analyze the clinical efficacy,the Common Terminology Criteria For Adverse Events version 5.0(CTCAE 5.0)was adopted to record and evaluate the treatment-related adverse events(TRAEs).The primary endpoints were progression-free survival(PFS)and overall survival(OS),the secondary endpoints were objective response rate(ORR),disease control rate(DCR),and safety.Results The median PFS was 11.7 months(95%CI:8.124-15.276 months),the median OS was 23.1 months(95%CI:19.508-26.692 months),the ORR was 46.3%,and the DCR was 87.0%.The most common TRAE at all levels was elevated alanine aminotransferase(51.9%),and the most common TRAE of grade 3/4 was hypertension(9.3%).No treatment-related death occurred.Conclusion For the treatment of HCC patients who developed TACE refractoriness,FOLFOX-HAIC combined LEN and ICIs is clinically safe and effective.(J Intervent Radiol,2024,33:610-615)
10.Biliary stent placement combined with 125I seed-strip implantation for malignant obstructive jaundice:analysis of prognostic factors
Zeyu YU ; Hui YU ; Lingfeng DIAO ; Ran YOU ; Bin LENG ; Qingyu XU ; Guowen YIN
Journal of Interventional Radiology 2024;33(7):758-762
Objective To investigate the factors affecting the prognosis of patients with malignant obstructive jaundice(MOJ)after receiving biliary stent placement combined with intraluminal brachytherapy with 125I seed-strip implantation.Methods The clinical data of 52 patients with MOJ,who received biliary stent placement combined with intraluminal brachytherapy with 125I seed-strip implantation at the Jiangsu Provincial Cancer Hospital of China between January 2019 and January 2023,were retrospectively analyzed.The difference value between preoperative and postoperative number of lymphoid immune cells was recorded as△X.X-tile software was used to calculate the optimal cut-off value of △X,based on which the patients were divided into two groups.Univariate and multivariate analysis were used to determine the risk factors for overall survival(OS).Results The mean survival time of the 52 patients was(201.0±32.1)days.Univariate analysis indicated that postoperative TACE,preoperative ALT,preoperative AST,△lymphocyte cell,△CD3+T cell,△CD8+T cell,△natural killer cell(NK)and △regulatory cell(Treg)were significantly associated with OS,the differences were statistically significant(all P<0.05).Multivariate analysis revealed that △lymphocyte cell(P=0.007)and △Treg(P=0.038)were the independent risk factors for OS.Conclusion For MOJ patients whose△lymphocyte is ≥0.237 or △Treg is ≥0.21,a longer OS can be expected after receiving the treatment of biliary stent placement combined with intraluminal brachytherapy with 125I seed-strip implantation.

Result Analysis
Print
Save
E-mail